Los Angeles 2003 Program
Biltmore Hotel, Los Angeles, California, USA
2nd Annual Meeting of the International Society of Pharmacogenomics (ISP)
JOINT MEETING WITH THE
Pacific Rim Association for Clinical Pharmacogenetics (PRACPG)
For a printable version of this page, click here.
This meeting was a satellite of the American Society of Human Genetics (ASHG)
Los Angeles, November 4-8, 2003 (for further information go to www.ashg.org).
November 3, 2003
7:00 – Posters go up
8:00-9:00 – Breakfast in Poster Area
9:00-9:15 – Welcome and Opening of Conference
9:15-10:00 – Keynote Lecture
"Pharmacogenetics as a predictive tool for a safer and more effective drug therapy - the state of the art"
Magnus Ingelman-Sundberg (Karolinska Institute, Stockholm, Sweden)
Introduced by Julio Licinio (University of California, Los Angeles, CA)
10:00-11:30 – Symposium # 1:
Advances in pharmacogenomics (three 30 min. talks)
Co-Chairs: Richard Weinshilboum and Junichi Azuma
1) "Advances in the pharmacogenetics of phase II drug metabolizing enzymes"
Richard Weinshilboum (Mayo Clinic)
2) "Clinical relevance of the NAT-2 gene polymorphism to prediction of hepatotoxicity in a treatment for tuberculosis."
Junichi Azuma (Department of Clinical Evaluation of Medicines and Therapeutics, Graduate School of Pharmaceutical Science, Osaka University)
3) "Large population study on cytochrome P450 (CYP2A6) genetic polymorphism"
Tetsuya Kamataki (Graduate School of Pharmaceutical Sciences, Hokkaido University)
11:30-12:10 - State of the Art Lecture
"The use of the pharmacogenomics in the process of drug development."
Olivier Grenet (Novartis)
Introduced by Magnus Ingelman-Sundberg
(Karolinska Institute, Stockholm, Sweden)
12:10-13:30 – Lunch
13:30-15:00 - Symposium #2
Pharmacogenomics and Clinical Medicine I (three 30 min. talks)
Co-Chairs: Toshiyuki Someya (Niigata University) and Daniel Nebert
1) "Pharmacogenomics and 'individualized drug therapy': exciting advances and disappointing setbacks"
Daniel W. Nebert, (University of Cincinnati Medical Center, Cincinnati)
2) "Pharmacogenomic - based therapeutic recommendations in clinical practice
Julia Kirchheiner (Humboldt University, Berlin, Germany)
3) "Pharmacogenetics of opioid analgesia: interplay between genes, enzymes, transporters and receptors"
Andrew A. Somogyi (University of Adelaide, Australia)
15:00-15:20 – Coffee Break (in poster area)
15:20-16:00 – State of the Art Lecture
"Latest results from deCode genetics"
Kari Stefansson, President and CEO of deCode Genetics, Reykjavik, Iceland
Introduced by Siu Wa Tang (University of Hong Kong)
16:00-17:30 - Symposium #3
Pharmacogenomics and Clinical Medicine II (three 30 min. talks)
Co-Chairs: Gerard Siest and Ted Inaba (University of Toronto, Canada)
1) "Integrating genomics, proteomics, and bioinformatics for cancer drug discovery"
John Weinstein (NCI)
2) "Pharmacogenetics in the treatment of breast cancer"
David Flockhart (Indiana University)
3) "Pharmacogenomics of cardiovascular risk therapy"
Ronald Krauss (Lawrence Berkeley National Laboratory)
17:30-18:30 – ISP Business Meeting (ISP members only) and PRACPG Business Meeting (PRACPG members only) – in parallel
19:00 – ISP Dinner
November 4, 2003
7:00-8:00 – Continental Breakfast (in poster area) and poster presentations
8:00-8:45 – Special Lecture
"Fifty years of pharmacogenetics: the lessons and the problems"
Urs A. Meyer (University of Basel, Switzerland)
Introduced by David Flockhart (Indiana University)
8:45-9:30 - State of the Art Lecture
"Pharmacogenomics of drugs affecting the cardiovascular system"
Gerard Siest (University of Nancy, France)
Introduced by Julia Kirchheiner (Humboldt University, Berlin, Germany)
9:30-10:00 – Coffee Break (in poster area)
10:00-12:00 – Symposium #4
Applications of pharmacogenomics to psychiatry (six 20 min. talks)
Co-Chairs: Julio Licinio and Bernard Lerer
1) "Pharmacogenetic studies of antipsychotics: 5-HT and DA candidate gene approach"
Norio Ozaki (Department of Psychiatry, Fujita Health Science University)
2) "Pharmacogenetic approaches to tardive dyskenesia"
Bernard Lerer (Hebrew University, Jerusalem)
3) "Pharmacogenetics of bipolar disorder"
Gustavo Turecki (McGill University, Montreal, Canada)
4) "Pharmacogenetics of serotoninergic pathways in depression"
Alessandro Serretti (San Raffaelle Hospital, Milano, Italy)
5) "Pharmacogenomics of depression: search for new targets"
Julio Licinio (University of California, Los Angeles, USA)
6) "Pharmacogenomics, neuroplasticity and antidepressant research - beyond the monoamine hypothesis"
Mitsuhiko Yamada (Showa University, Karasuyama Hospital)
12:00-13:20 – Lunch
13:20-14:50 – Round Table
Pharmacogenetics research in ethnically-identified populations
Julio Licinio (University of California, Los Angeles) and Charles Weijer (Dalhousie University, Nova Scotia, Canada)
15:00-16:00 – Keynote Lecture
"The international haplotype map consortium"
Francis Collins (Director, National Human Genome Research Institute, NIH)
Introduced by Julio Licinio (University of California, Los Angeles, CA)
16:00-16:45 – State of the Art Lecture
"Candidate gene studies in pharmacogenetics"
David Goldstein (University College, London, UK)
Introduced by Christopher Reist (University of California, Irvine, CA)
16:45-17:00 – Coffee Break
17:00-17:45 – Special Lecture
"Pharmacogenomics in drug development: ethical-societal and technical aspects"
Tamas Bartfai (Scripps Institute, San Diego, CA)
Introduced by Ma-Li Wong (University of California, Los Angeles, CA)
16:00-16:10 – Closing of the Meeting
17:00-18:00 – ISP and PRCP Council Meeting (including Committee Chairs)